European Molecular Diagnostics Market revenue to cross $8.09 Bn by 2028

Published Date: 2022-08-22

Request a sample

European Molecular Diagnostics Market size is poised to reach USD 8.09 billion by 2028, according to a latest forecast report by Graphical Research.

The popularity of point-of-care diagnostic services will help the market growth depict consistency through 2028. Research and development strategies are contributing to the advancement of healthcare diagnostic services. In Europe, the demand for point-of-care diagnostics and personalized medicines continues to escalate. PCR and DNA sequencing methods are also witnessing massive innovation across the region. Since the introduction of new technologies and accurate tests are pivotal to precision medicine development.

In past years, molecular diagnostic tests, including Real-Time PCR (RT-PCR), were considered a niche technology. The ongoing COVID-19 pandemic has, however, resulted in the authorization of new tests and expansion of molecular diagnostics testing infrastructure. For instance, in May 2022, Abbott gained the Emergency Use Authorization from the U.S. Food and Drug Administration for its rapid point-of-care test, ID Now COVID-19 2.0. This system was designed to detect the SARS-CoV-2 nucleic acid in nasopharyngeal swab specimens within 7 days of symptom onset.

Likewise, government initiatives have been launched to support molecular diagnostics platforms. In addition, funding programs are also introduced to train healthcare experts in the field of personalized medicine to boost patient engagement.

The adoption of molecular diagnostic instruments is slated to witness healthy growth during the forecast period, given the rising complexity of managing infectious diseases and the ever-growing medical needs. In November 2021, Roche launched a molecular laboratory instrument, the cobas 5800 System. This instrument was designed to help address challenges faced in laboratories due to the rise of patient testing and the need for diverse testing options. Such initiatives to deliver quality patient care will favor molecular diagnostic service providers in Europe.

The Europe molecular diagnostics market from hybridization technology segment will amass considerable gains by 2028, due to the emergence of molecular hybridization as a promising drug design strategy for cancer treatment. Research service providers are also expanding their laboratory footprint to increase testing capacity. These factors will further drive the popularity of hybridization since the technology is crucial in research and clinical lab techniques.

Browse detailed statistical insights from the report, “Europe Molecular Diagnostics Market Forecast 2028 By Application (Infectious Disease Diagnostics {COVID-19, HIV, CT/NG, Hepatitis B, Hepatitis C, RSV, Flu, Tuberculosis}, Oncology Testing, Genetic Disease Testing), By Technology (Polymerase Chain Reaction [PCR], Hybridization, Sequencing, Isothermal Nucleic Acid Amplification Technology [INAAT], Microarrays), By Product (Instruments, Reagents & Kits), By End-use (Diagnostics Laboratories, Hospitals & Clinics), Research Report, Country Outlook (Germany, UK, France, Spain, Portugal, Italy, Russia, Denmark, Norway, Sweden), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

The demand for molecular diagnostics for infectious disease treatment will rise substantially till 2028, considering the growing number of people with viral hepatitis in the region. According to the WHO, nearly 10 million to 14 million people are diagnosed with viral hepatitis B and C in Europe, which will likely bolster the need for efficient diagnostic techniques.

The Europe molecular diagnostics market from the hospitals & clinics segment is set to register a revenue of around USD 3,520 million by 2028, attributed to the accelerating hospital construction and healthcare infrastructure development projects. The burden of chronic diseases like cancer will further augment the demand for molecular diagnostics in healthcare facilities like clinics in the region.

The UK molecular diagnostics market accounted for USD 3,980 million revenue in 2021. Research and development activities and healthcare infrastructure expansions are becoming more prevalent in the country. These factors, in addition to the rising acceptance of personalized therapy, will provide lucrative growth opportunities for the market in the UK.

The Europe molecular diagnostics market research report includes in-depth coverage of the industry with estimates & forecast in terms of volume in Kilotons & revenue in USD Million from 2017 to 2028, for the following segments:

Europe Market, By Product

  • Instruments
  • Reagents & Kits

Europe Market, By Technology

  • Polymerase Chain Reaction (PCR)
  • Hybridization
  • Sequencing
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Microarrays
  • Others

Europe Market, By Application

  • Infectious Disease Diagnostics 
    • COVID-19
    • HIV
    • CT/NG
    • Hepatitis B
    • Hepatitis C
    • RSV
    • Flu
    • Tuberculosis
    • Others 
  • Oncology Testing
  • Genetic Disease Testing
  • Others

Europe Market, By End-use

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

The above information has been provided for the following countries:

  • Europe   
    • Germany
    • UK
    • France
    • Italy
    • Spain